Mimedx Group, Inc. (MDXG) SEC Filing 10-K Annual report for the fiscal year ending Wednesday, December 31, 2014

Earnings Press Release
10-K Annual Report
10-K YoY Changes
Mimedx Group, Inc.
Ticker: MDXG CIK: 1376339

Exhibit 99.1

PRESS RELEASE CONTACT:

MICHAEL SENKEN

PHONE: (770) 651-9100

MIMEDX ANNOUNCES 2014 RECORD REVENUE

AND FIRST FULL YEAR OPERATING PROFIT

Company Records Revenue of $118.2 million, Operating income of $7.1 million

and Net Income of $6.2 million

MARIETTA, Georgia, February 26, 2015

(PR Newswire) - MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today its record results for the fourth quarter and full year ended December 31, 2014.

Full Year and Fourth Quarter 2014 Highlights


•	Full Year 2014 revenue of $118.2 million doubles 2013 revenue and exceeds upper end of guidance


•	Q4 revenue of $39.6 million increases 120% over Q4 2013


•	Q4 revenue exceeds $38.3 million upper end of guidance by $1.3 million


•	Q4 is 13^th consecutive quarter of meeting or exceeding revenue guidance


•	2014 is 3^rd consecutive fiscal year of meeting or exceeding guidance


•	Full year 2014 Wound Care sales more than doubles full year 2013


•	Q4 Wound Care sales grows 24% sequentially over Q3 2014


•	2014 Commercial Accounts and Government Accounts revenue grows 208% and 18%, respectively


•	First annual operating income of 6% of revenue recorded for full year 2014


•	Q4 is 12^th consecutive quarter of positive Adjusted EBITDA*


•	Full Year Adjusted EBITDA* is 17.5% of revenue and a 278% improvement over full year 2013


•	Q4 Adjusted EBITDA* is 22% of revenue and a 542% improvement over Q4 2013


•	2014 Cash Flow from Operating Activities grows to $16.8 million

Full Year and Fourth Quarter Results

For the year ended December 31, 2014, the Company recorded record revenue of $118.2 million, a $59.0 million or 100% increase over revenue of $59.2 million for full year 2013. The Company’s gross margins for the year ended December 31, 2014, were 89% as compared to 84% in the same period in 2013. Adjusted EBITDA* for the year ended December 31, 2014, were $20.7 million, a $15.2 million or 278% improvement, as compared to Adjusted EBITDA* of $5.5 million for the full year 2013. Net Income for the year ended December 31, 2014, was $6.2 million, or $0.05 per diluted common share, a $10.3 million improvement, as compared to the Net Loss of $4.1 million, or $0.04 per diluted common share, in the prior year same period.

The Company recorded record revenue for the fourth quarter of 2014 of $39.6 million, a $21.6 million or 120% increase over 2013 fourth quarter revenue of $18.0 million, and sequentially, a $6.1 million or 18% increase over third quarter of 2014 revenue. The Company’s gross margins for the quarter ended December 31, 2014, were 91% as compared to 83% in the fourth quarter of 2013. Adjusted EBITDA* for the quarter ended December 31, 2014, were $8.5 million, a $7.2 million or 542% improvement, as compared to Adjusted EBITDA* of $1.3 million for the fourth quarter of 2013. The Net Income for the fourth quarter of 2014 was $3.8 million, or $0.03 per diluted common share, a $5.3 million improvement, as compared to the Net Loss of $1.4 million, or $0.01 per diluted common share, in the 2014 fourth quarter.

The following information was filed by Mimedx Group, Inc. (MDXG) on Thursday, February 26, 2015 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Mimedx Group, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Mimedx Group, Inc..

Continue

Please wait while we load the requested 10-K report or click the link below:

https://last10k.com/sec-filings/report/1376339/000137633915000040/mdxg-20141231x10k.htm